Kling Biotherapeutics

🛫Are you heading west for J.P. Morgan’s Annual Healthcare Conference in January? Connect with our CEO, Michael Koslowski, and CSO, Stefano Gullà in San Francisco🌉 where they are looking forward to connecting 🤝with potential investors and partners to discuss future strategic developments to advance our robust pipeline of therapeutic #antibodies targeting novel antigens discovered using our clinically and commercially validated primary B-cell screening platform technologies. Get in touch to schedule a meeting and learn more about #Kling's approach to leveraging disease-fighting antibodies derived from elite responders using the link in the first comment below. See you there! #JPM2025 #immunooncology #antibodytherapeutics #infectiousdiseases #cancer #KlingSelect #KlingEvolve #TuLibs

Introducing TuLibs (tumor libraries) – the latest addition to our powerful primary B-cell screening platform technologies. Produced with our B-cell immortalization platform Kling-evolve, TuLibs is a new tool for discovering therapeutic antibodies and tumor-associated targets from tumor-infiltrating B cells (#TIBs). To date, we have created and characterized 18 tumor samples across 10 solid tumor indications which include #Glioblastoma, #LungCancer, #BreastCancer, #KidneyCancer, #OvarianCancer, #EndometrialCancer, #PancreaticCancer, and #Mesothelioma. Take a closer look below 👀 at TuLibs 👇! Reach out to Kling Biotherapeutics for partnership and collaboration opportunities to develop novel therapeutics from existing #TuLibs or new libraries derived from patient’s post-immunotherapy, targeting high unmet medical needs. #drugdiscovery #immunooncology #antibodytherapeutics #drugdevelopment #KlingSelect #KlingEvolve

Vulnerabilities in pandemic preparedness quickly became evident with the rapid global spread of COVID-19 in 2020 which triggered seismic shifts in every aspect of health and medicine and accelerated the development of #vaccine, diagnostic, and therapeutic technologies. While it may seem that the world is now better prepared for the next large #outbreak, are we truly ready?   Recently, the Democratic Republic of Congo (DRC) has become the epicenter of a mysterious flu-like illness labeled “Disease X”. According to the latest report from the World Health Organization (WHO), all 406 cases and 31 deaths, (Case Fatality Ratio or CFR of 7.6%) have occurred in the Kwango Province of the DRC. The outbreak is still ongoing and there have been several additional deaths outside of health facilities (community deaths), requiring further investigation. Earlier this year, the DRC also saw a resurgence in mpox cases which led the WHO to declare #mpox as a public health emergency of international concern (#PHEIC) for the second time in two years. Read more about the “Disease X” outbreak here: https://bit.ly/4f3yMC8   Rapid countermeasures are essential to combat the spread of emerging infectious diseases and protect medical first responders. At #Kling we take an ‘effective antibody first’ discovery approach to rapidly discover neutralizing #antibodies and #antigen targets,🎯from #Bcells of patients of responses. Our cutting-edge technology successfully discovered the fully human Respiratory Syncytial Virus (RSV) neutralizing #antibody #Nirsevimab that prevents RSV in infants and children under 24 months.   As global concerns rise about emerging pandemic threats, we continue our mission of developing novel antibody-based therapeutics to improve outcomes for patients with infectious diseases and #cancer. Follow #KlingBio on LinkedIn and X / Twitter @KlingBio_ or check out our website using the link in the comments below to stay up to date on how we are revolutionizing #antibody therapeutics. #drugdiscovery #immunooncology #antibodytherapeutics #drugdevelopment #KlingSelect #KlingEvolve

📢Exciting news! 📢   Kling Biotherapeutics welcomes leading drug development experts Alessandra Villa as Director of Platform Development and Rob Roovers as Director of Preclinical Development as we further strengthen our leadership team to progress our pipeline across #cancer and #infectiousdiseases.   Alessandra and Rob’s appointments come at a pivotal time of growth📈 and development for #Kling as we advance the identification of therapeutic #antibodies from B-cells of ‘exceptional responders’ using our groundbreaking commercially validated primary B-cell selection and evolution platform.   Learn more about Alessandra and Rob’s expertise in the full press release here👉https://bit.ly/4fahC5N   #antibodytherapeutics #cancer #oncology #immunotherapy #immunooncology

📢Exciting news! 📢   Kling Biotherapeutics welcomes leading drug development experts Alessandra Villa as Director of Platform Development and Rob Roovers as Director of Preclinical Development as we further strengthen our leadership team to progress our pipeline across #cancer and #infectiousdiseases.   Alessandra and Rob’s appointments come at a pivotal time of growth📈 and development for #Kling as we advance the identification of therapeutic #antibodies from B-cells of ‘exceptional responders’ using our groundbreaking commercially validated primary B-cell selection and evolution platform.   Learn more about Alessandra and Rob’s expertise in the full press release here👉https://bit.ly/4fahC5N   #antibodytherapeutics #cancer #oncology #immunotherapy #immunooncology

Listen 📣 to our CSO, Stefano Gullà delve into the crucial role that B-cells play in the fight against #cancer in the latest #optimumperspectives #podcast edition.   #Kling is well-positioned to discover new insights from tumor-infiltrating B-cells with its B-cell immortalization technology.   #cancer #immunotherapy #bcells #oncology #therapeutics #research #innovation #medicine #health

“Educate. Advocate. Act Now” Kling Biotherapeutics is proud to support World AMR Awareness Week (#WAAW) from 18-24 November. Contributing to 5 million deaths every year, antimicrobial resistance (#AMR) is a global health crisis with many socioeconomic consequences. This worldwide campaign aims to raise awareness and understanding of AMR, alongside promoting best practices among the public, OneHealth stakeholders, and policymakers, to reduce the emergence and spread of drug-resistant infections. At #Kling, our clinically validated B cell immortalization technology has been successful in the discovery of the fully human Respiratory Syncytial Virus (RSV) neutralizing antibody #Nirsevimab that prevents RSV in infants and children under 24 months. By following an ‘effective antibody first’ discovery approach, Kling’s platform enables the discovery of relevant, completely novel antigen targets to help battle illnesses including cancer and #infectiousdiseases. AMR is invisible, but its victims are not! Let’s encourage one another to share our experiences of AMR and learn about its impact, to promote urgent global action. #WorldAMRAwarenessWeek #AntimicrobialResistance #drugdiscovery #drugdevelopment #Antimicrobial #AMRsurvivors

📢Meet us at BIO-EUROPE in Stockholm!   Don’t miss the opportunity to connect with our CEO Michael Koslowski and CSO Stefano Gullà next week at #BIOEurope2024, from 4-6 November in Stockholm, Sweden!   📲 Connect with Michael and Stefano onsite to learn more about the latest advancements on our clinically validated, primary B-cell selection and evolution platform technologies, Kling-Select and Kling-Evolve.   #Kling's proprietary primary B-cell screening platform efficiently identifies therapeutic targets and antibodies from B-cells of ‘exceptional responders’, which, having been developed in the human body, have shown to be safe and effective in helping these individuals successfully battle illnesses including #cancer and #infectiousdiseases.   Presented by Informa Connect and #EBDGroupPartnering, #BIOEurope has been where CEOs and investors gather to connect with professionals spanning the global life science ecosystem to propel dealmaking and innovation for more than 30 years,   #drugdiscovery #immunooncology #antibodytherapeutics

📣Meet Kling Biotherapeutics at #PEGSEurope!   Kling Biotherapeutics will be presenting two poster presentations on its proprietary primary B-cell selection and evolution platform technologies, Kling-Select and Kling-Evolve at the Protein & Antibody Engineering Summit (#PEGS) Europe in Barcelona, Spain from the 5-7 November.   📌Poster Title: Highly efficient capture of circulating and tissue-infiltrating B cell repertoires from multiple species: Kling-Select 📢Presenter: Casper Marsman, Senior Scientist – B Cell Platform Lead 🔢Presentation Number: A073   📌Poster Title: Kling-Evolve as a tool for rapid response to emerging variants and pandemic preparedness: directed evolution of variant-specific antibody from immortalized B cells 📢Presenter: Alessandra Villa, Director of Discovery Platforms 🔢Presentation Number: A073   Posters will be displayed in the Exhibit Hall at the following dates 📅and times🕘:   Tuesday, 5 November from 10:30 – 19:35 CET Wednesday, 6 November from 10:30 -17:15 CET Thursday, 7 November from 10:00 – 13:55 CET   We are proud to be sharing key applications on our clinically validated, proprietary, B cell immortalization, screening and antibody optimization platform technologies, Kling-Select and Kling-Evolve. Read more about our poster presentations at #PEGS using the link in the first comment below👇.   🤝Connect with Casper and Alessandro at the #PEGSummit to learn more about Kling's approach to leveraging disease fighting #antibodies derived from ‘elite responders.’   We can't wait to see you there!   #proteomics #drugdiscovery #immunooncology #antibodytherapeutics #drugdevelopment   Read the full PR here👉https://bit.ly/4fhIaCU

In the latest publication of Drug Discovery World, our Chief Scientific Officer Stefano Gullà, sheds light🔦on the crucial role of #Bcells in the fight against #cancer, and the potential they have to develop new targeted therapies.   Although cancer #immunotherapies have raised the standard of care in #oncology, their drawbacks are well known, necessitating the need for more safe and efficacious options.   Stefano emphasizes that B cells, particularly tumor infiltrating B cells (TIBs), deserve a closer look and explores their potential in developing novel cancer immunotherapies.   At Kling Biotherapeutics, we look into the human immune response to discover new targets and new therapeutics with our clinically validated B-cell immortalization, screening and evolution technology to ultimately improve patient outcomes.   Learn more about tumor infiltrating B Cells here👉 https://bit.ly/3YnZjDR   #drugdiscovery #drugdevelopment #immunooncology #antibodytherapeutics